1. Home
  2. ACRS vs SSYS Comparison

ACRS vs SSYS Comparison

Compare ACRS & SSYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$4.51

Market Cap

868.5M

Sector

Health Care

ML Signal

N/A

Logo Stratasys Ltd. (Israel)

SSYS

Stratasys Ltd. (Israel)

N/A

Current Price

$8.49

Market Cap

719.7M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
SSYS
Founded
2012
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
868.5M
719.7M
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
ACRS
SSYS
Price
$4.51
$8.49
Analyst Decision
Strong Buy
Buy
Analyst Count
12
4
Target Price
$10.18
★ $12.00
AVG Volume (30 Days)
★ 2.4M
574.3K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.01
N/A
EPS
N/A
★ N/A
Revenue
★ $1,683,000.00
N/A
Revenue This Year
N/A
$2.56
Revenue Next Year
N/A
$3.81
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$7.34
52 Week High
$6.60
$12.78

Technical Indicators

Market Signals
Indicator
ACRS
SSYS
Relative Strength Index (RSI) 40.21 56.54
Support Level $4.99 $7.99
Resistance Level $5.15 $8.96
Average True Range (ATR) 0.32 0.25
MACD -0.03 0.08
Stochastic Oscillator 19.62 72.88

Price Performance

Historical Comparison
ACRS
SSYS

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About SSYS Stratasys Ltd. (Israel)

Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.

Share on Social Networks: